Skip to main content

Table 2 Age-standardized prevalence (95% CI) of comorbidities in men and women with gout at the time of first diagnosis

From: Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy

  Gout cases
(N = 14,113)
Men
(N = 9513),
prevalence (%)
95% CI Women
(N = 4600),
prevalence (%)
95% CI
Comorbidities suggested to increase SU level
 Psoriasis 3.7 2.8–4.5 3.3 2.6–4.1
 Organ transplantation 1.3 0.8–1.8 1.8 0.9–2.6
 Renal disease 8.2 7.4–9.0 8.3 6.8–9.8
 Use of diuretics 21.9 20.9–22.8 24.1 22.7–25.6
 Obesity 10.2 8.9–11.6 12.5 10.8–14.3
 Alcoholism 5.5 4.7–6.3 3.5 2.1–4.8
Other comorbidities
 Diabetes 8.7 8.1–9.3 9.9 8.9–10.9
 Hypertension 40.1 38.6–41.6 39.4 36.9–41.9
 Coronary heart disease 9.4 9.0–9.9 6.4 5.8–7.0
 Congestive heart failure 7.7 7.3–8.1 6.6 6.0–7.1
 Atrial fibrillation 9.0 8.4–9.5 6.0 5.4–6.5
 Stroke 4.1 3.7–4.5 3.3 2.8–3.7
 Thromboembolism 5.2 4.8–5.6 6.6 5.8–7.5
 Peripheral vascular disease 2.1 1.9–2.3 2.1 1.7–2.5
 COPD 2.4 2.1–2.6 3.1 2.6–3.5
  1. CI confidence interval, COPD chronic obstructive pulmonary disease, SU serum urate